United Therapeutics Statistics Share Statistics United Therapeutics has 45.23M
shares outstanding. The number of shares has increased by 1.38%
in one year.
Shares Outstanding 45.23M Shares Change (YoY) 1.38% Shares Change (QoQ) 0.43% Owned by Institutions (%) 98.61% Shares Floating 44.08M Failed to Deliver (FTD) Shares 4,904 FTD / Avg. Volume 0.81%
Short Selling Information The latest short interest is 1.6M, so 3.55% of the outstanding
shares have been sold short.
Short Interest 1.6M Short % of Shares Out 3.55% Short % of Float 4.66% Short Ratio (days to cover) 4.05
Valuation Ratios The PE ratio is 13.34 and the forward
PE ratio is 10.46.
United Therapeutics's PEG ratio is
0.52.
PE Ratio 13.34 Forward PE 10.46 PS Ratio 5.54 Forward PS 4 PB Ratio 2.47 P/FCF Ratio 14.76 PEG Ratio 0.52
Financial Ratio History Enterprise Valuation United Therapeutics has an Enterprise Value (EV) of 14.55B.
EV / Sales 5.06 EV / EBITDA 8.8 EV / EBIT 10.96 EV / FCF 13.47
Financial Position The company has a current ratio of 5.25,
with a Debt / Equity ratio of 0.05.
Current Ratio 5.25 Quick Ratio 5.03 Debt / Equity 0.05 Debt / EBITDA 0.18 Debt / FCF 0.28 Interest Coverage 32.1
Financial Efficiency Return on Equity is 18.55% and Return on Invested Capital is 15.44%.
Return on Equity 18.55% Return on Assets 16.23% Return on Invested Capital 15.44% Revenue Per Employee $2.2M Profits Per Employee $915.79K Employee Count 1,305 Asset Turnover 0.39 Inventory Turnover 1.96
Taxes Income Tax 343.9M Effective Tax Rate 22.35%
Stock Price Statistics The stock price has increased by -9.99% in the
last 52 weeks. The beta is 0.57, so United Therapeutics's
price volatility has been higher than the market average.
Beta 0.57 52-Week Price Change -9.99% 50-Day Moving Average 297.7 200-Day Moving Average 329.46 Relative Strength Index (RSI) 53.58 Average Volume (20 Days) 602,898
Income Statement In the last 12 months, United Therapeutics had revenue of 2.88B
and earned 1.2B
in profits. Earnings per share was 26.44.
Revenue 2.88B Gross Profit 2.57B Operating Income 1.38B Net Income 1.2B EBITDA 1.65B EBIT 1.58B Earnings Per Share (EPS) 26.44
Full Income Statement Balance Sheet The company has 1.7B in cash and 300M in
debt, giving a net cash position of 1.4B.
Cash & Cash Equivalents 1.7B Total Debt 300M Net Cash 1.4B Retained Earnings 7.22B Total Assets 7.91B Working Capital 3.3B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 1.33B
and capital expenditures -246.5M, giving a free cash flow of 1.08B.
Operating Cash Flow 1.33B Capital Expenditures -246.5M Free Cash Flow 1.08B FCF Per Share 23.91
Full Cash Flow Statement Margins Gross margin is 89.24%, with operating and profit margins of 47.86% and 41.53%.
Gross Margin 89.24% Operating Margin 47.86% Pretax Margin 53.49% Profit Margin 41.53% EBITDA Margin 57.5% EBIT Margin 47.86% FCF Margin 37.55%
Dividends & Yields UTHR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 7.49% FCF Yield 6.78%
Dividend Details Analyst Forecast The average price target for UTHR is $364.5,
which is 21.3% higher than the current price. The consensus rating is "Buy".
Price Target $364.5 Price Target Difference 21.3% Analyst Consensus Buy Analyst Count 13
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value $470.9 Lynch Upside 56.74% Graham Number 291.23 Graham Upside -3.07%
Stock Splits The last stock split was on Sep 23, 2009. It was a
forward
split with a ratio of 2:1.
Last Split Date Sep 23, 2009 Split Type forward Split Ratio 2:1
Scores Altman Z-Score 14.1 Piotroski F-Score 7
